
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k050536
B. Purpose for Submission: Notification of intent to manufacture and market
the device: Quest Diagnostics Immunoassay/TDM Controls
C. Measurand:
• 17-α-Hydroxyprogesterone • Lidocaine
• Acetaminophen • Lithium
• Aldosterone • LH
• Alpha Fetoprotein (AFP) • NAPA
• Amikacin • PTH, Intact
• Androstenedione • Phenobarbital
• Caffeine • Phenytoin
• Carbamazepine • Primidone
• CEA • Procainamide
• Chloramphenicol • Progesterone
• Cortisol • Prolactin
• C-Peptide • PAP
• DHEA Sulfate • PSA
• Digoxin • PSA, Free
• Disopyramide • Quinidine
• Estradiol • Salicylate
• Estriol, Free • T3, Free
• Ethosuximide • T3, Total
• Ferritin • T4, Free
• Folate • T4, Total
• FSH • Testosterone
• Gastrin • Theophylline
• Gentamicin • Tobramycin
• Homocysteine • TSH
• hCG • Valproic Acid
• hGH • Vancomycin
• Immunoglobulin E (IgE) • Vitamin B12
• Insulin
D. Type of Test:
Quality Control Material
E. Applicant:
Bio-Rad Laboratories
F. Proprietary and Established Names:

--- Page 2 ---
Proprietary – Quest Diagnostics Immunoassay/TDM Controls
Established – Multi-Analyte Controls, Assayed and Unassayed
G. Regulatory Information:
1. Regulation section:
21 CFR 862.1660
2. Classification:
Class I
3. Product code:
JJY
4. Panel:
75, Chemistry
H. Intended Use:
1. Intended use(s):
See indications for use below
2. Indication(s) for use:
Quest Diagnostics Immunoassay/TDM Control is intended for use as a
quality control serum to monitor the precision of laboratory testing
procedures listed in this package insert.
3. Special conditions for use statement(s):
For prescription use only
4. Special instrument requirements:
Not applicable
I. Device Description:
Quest Diagnostics Immunoassay/TDM Control is prepared from human
serum with added constituents of human and animal origin, chemicals and
therapeutic drugs. The product is provided in lyophilized form for increased

--- Page 3 ---
stability. Each level of control contains 4 – 5ml bottles.
Each human donor unit used to manufacture this control was tested by FDA
accepted methods and found to be non-reactive for Hepatitis B Surface
Antigen (HBsAg), antibody to Hepatitis C (HCV) and antibody to HIV-1/HIV-2.
J. Substantial Equivalence Information:
1. Predicate device name(s):
Bio-Rad Laboratories Lyphochek Immunoassay Plus Control
2. Predicate 510(k) number(s):
k981532
3. Comparison with predicate:
Characteristics Quest Diagnostics Bio-Rad Laboratories
Immunoassay/TDM Control Lyphochek Immunoassay Plus Control
(New Device) (Predicate Device K981532)
Similarities
Intended Use Quest Diagnostics Immunoassay/TDM Control is Lyphochek Immunoassay Plus Control is intended
intended for use as a quality control serum to monitor for use as an assayed quality control serum to
the precision of laboratory testing procedures for the monitor the precision of laboratory testing
analytes listed in the package insert. procedures for the analytes listed in the package
insert.
Form Lyophilized Lyophilized
Matrix Human Serum Human Serum
Preservatives Does not Contains preservatives Does not Contains preservatives
Storage 2°C to 8°C 2°C to 8°C
(Unopened)
Until expiration date Until expiration date
Differences
Reconstituted Vial 7 days at 2 to 8°C 7 days at 2°C to 8°C
Claim with the following exceptions: with the following exceptions:
(1) C-Peptide, Folate and PSA 3 days (1) Folate and PSA 3 days,
(2) Gastrin, Free PSA and Intact PTH assay (2) C-Peptide 1 day,
immediately (3) Intact PTH 16 hours,
(4) ACTH, Calcitonin, Gastrin and Free PSA assay
immediately
After No claims All analytes 30 days at -10 to -20°C
Reconstituting
and Freezing
Contains the following analytes: Contains the following analytes:
Analytes
• 17-α- • Lidocaine • 11-Deoxycortisol • Immunoglobulin E
Hydroxyprogesterone (IgE)
• Acetaminophen • Lithium • 17-α- • Insulin
Hydroxyprogesterone
• Aldosterone • LH • Acetaminophen • Lidocaine
• Alpha Fetoprotein (AFP) • NAPA • ACTH) • Lithium
• Amikacin • PTH, Intact • Alpha Fetoprotein • LH
(AFP)
• Androstenedione • Phenobarbital • Amikacin • NAPA

[Table 1 on page 3]
Characteristics		Quest Diagnostics
Immunoassay/TDM Control
(New Device)	Bio-Rad Laboratories
Lyphochek Immunoassay Plus Control
(Predicate Device K981532)	
	Similarities			
Intended Use		Quest Diagnostics Immunoassay/TDM Control is
intended for use as a quality control serum to monitor
the precision of laboratory testing procedures for the
analytes listed in the package insert.	Lyphochek Immunoassay Plus Control is intended
for use as an assayed quality control serum to
monitor the precision of laboratory testing
procedures for the analytes listed in the package
insert.	
Form		Lyophilized	Lyophilized	
Matrix		Human Serum	Human Serum	
Preservatives		Does not Contains preservatives	Does not Contains preservatives	
Storage
(Unopened)		2°C to 8°C
Until expiration date	2°C to 8°C
Until expiration date	
	Differences			
Reconstituted Vial
Claim		7 days at 2 to 8°C
with the following exceptions:
(1) C-Peptide, Folate and PSA 3 days
(2) Gastrin, Free PSA and Intact PTH assay
immediately	7 days at 2°C to 8°C
with the following exceptions:
(1) Folate and PSA 3 days,
(2) C-Peptide 1 day,
(3) Intact PTH 16 hours,
(4) ACTH, Calcitonin, Gastrin and Free PSA assay
immediately	
After
Reconstituting
and Freezing		No claims	All analytes 30 days at -10 to -20°C	
Analytes				

--- Page 4 ---
Characteristics Quest Diagnostics Bio-Rad Laboratories
Immunoassay/TDM Control Lyphochek Immunoassay Plus Control
(New Device) (Predicate Device K981532)
• Caffeine • Phenytoin • Aldosterone • Netilmicin
• Carbamazepine • Primidone • Amitriptyline • Nortriptyline
• CEA • Procainamide • Androstenedione • PTH
• Chloramphenicol • Progesterone • Caffeine • Phenobarbital
• Cortisol • Prolactin • Calcitonin • Phenytoin
• C-Peptide • PAP • Carbamazepine, Free • Phenytoin, Free
• DHEA Sulfate • PSA • Carbamazepine • Primidone
• Digoxin • PSA, Free • CEA • Procainamide
• Disopyramide • Quinidine • Chloramphenicol • Progesterone
• Estradiol • Salicylate • Cortisol • Prolactin
• Estriol, Free • T3, Free • C-Peptide • PAP
• Ethosuximide • T3, Total • DHEA Sulfate • Propanolol
• Ferritin • T4, Free • Digoxin • PSA
• Folate • T4, Total • Disopyramide • PSA, Free
• FSH • Testosterone • Cyclosporine • Quinidine
• Gastrin • Theophylline • Desipramine • Salicylate
• Gentamicin • Tobramycin • DHEA • T3 Free
• Homocysteine • TSH • Estradiol • T3 Total
• hCG • Valproic Acid • Estriol, Free • T3 Uptake
• hGH • Vancomycin • Estriol, Total • T4 Free
• Immunoglobulin E (IgE) • Vitamin B12 • Estrogens, Total • T4 Total
• Insulin • Ethosuximide • TCA Screen
• Ferritin • Testosterone
• Does not Contains the following analytes: • Folate • Testosterone, Free
• 11-Deoxycortisol • TIBC • Flecainide • Theophylline
• Aldosterone • HCG-Beta Subunit • FSH • Tobramycin
• Amitriptyline • Imipramine • Gastrin • TSH
• Calcitonin • Netilmicin • Gentamicin • Valproic Acid
• Carbamazepine, Free • Nortriptyline • hCG and hCG-Beta • Valproic Acid, Free
Subunit
• Cyclosporine* • Phenytoin, Free • hGH • Vancomycin
• Desipramine • Propanolol • Imipramine • Vitamin B12
• DHEA • T3 Uptake • 25-Hydroxy Vitamin D • Immunoglobulin A
(IgA)
• Estriol, Total • TCA Screen • Angiotensin I • Immunoglobulin G
(IgG)
• Estrogens, Total • Testosterone, Free • Fructosamine • Immunoglobulin M
(IgM)
• Flecainide • Valproic Acid, Free • Glucagon • Somatomedin-C
• 25-Hydroxy Vitamin D • Immunoglobulin A • Iron • TBG
(IgA)
• Angiotensin I • Immunoglobulin G • TIBC • Thyroglobulin
(IgG)
• Fructosamine • Immunoglobulin M Does not Contains the following analytes:
(IgM)
• Glucagon • Somatomedin-C • Homocysteine
• Iron • TBG
• Thyroglobulin
K. Standard/Guidance Document Referenced (if applicable):
No standard or guidance document was referenced.
L. Test Principle:
Not Applicable

[Table 1 on page 4]
Characteristics	Quest Diagnostics
Immunoassay/TDM Control
(New Device)	Bio-Rad Laboratories
Lyphochek Immunoassay Plus Control
(Predicate Device K981532)
	• Caffeine • Phenytoin
• Carbamazepine • Primidone
• CEA • Procainamide
• Chloramphenicol • Progesterone
• Cortisol • Prolactin
• C-Peptide • PAP
• DHEA Sulfate • PSA
• Digoxin • PSA, Free
• Disopyramide • Quinidine
• Estradiol • Salicylate
• Estriol, Free • T3, Free
• Ethosuximide • T3, Total
• Ferritin • T4, Free
• Folate • T4, Total
• FSH • Testosterone
• Gastrin • Theophylline
• Gentamicin • Tobramycin
• Homocysteine • TSH
• hCG • Valproic Acid
• hGH • Vancomycin
• Immunoglobulin E (IgE) • Vitamin B12
• Insulin	• Aldosterone • Netilmicin
• Amitriptyline • Nortriptyline
• Androstenedione • PTH
• Caffeine • Phenobarbital
• Calcitonin • Phenytoin
• Carbamazepine, Free • Phenytoin, Free
• Carbamazepine • Primidone
• CEA • Procainamide
• Chloramphenicol • Progesterone
• Cortisol • Prolactin
• C-Peptide • PAP
• DHEA Sulfate • Propanolol
• Digoxin • PSA
• Disopyramide • PSA, Free
• Cyclosporine • Quinidine
• Desipramine • Salicylate
• DHEA • T3 Free
• Estradiol • T3 Total
• Estriol, Free • T3 Uptake
• Estriol, Total • T4 Free
• Estrogens, Total • T4 Total
• Ethosuximide • TCA Screen
• Ferritin • Testosterone
	• Does not Contains the following analytes:
• 11-Deoxycortisol • TIBC
• Aldosterone • HCG-Beta Subunit
• Amitriptyline • Imipramine
• Calcitonin • Netilmicin
• Carbamazepine, Free • Nortriptyline
• Cyclosporine* • Phenytoin, Free
• Desipramine • Propanolol
• DHEA • T3 Uptake
• Estriol, Total • TCA Screen
• Estrogens, Total • Testosterone, Free
• Flecainide • Valproic Acid, Free
• 25-Hydroxy Vitamin D • Immunoglobulin A
(IgA)
• Angiotensin I • Immunoglobulin G
(IgG)
• Fructosamine • Immunoglobulin M
(IgM)
• Glucagon • Somatomedin-C
• Iron • TBG
• Thyroglobulin	• Folate • Testosterone, Free
• Flecainide • Theophylline
• FSH • Tobramycin
• Gastrin • TSH
• Gentamicin • Valproic Acid
• hCG and hCG-Beta • Valproic Acid, Free
Subunit
• hGH • Vancomycin
• Imipramine • Vitamin B12
• 25-Hydroxy Vitamin D • Immunoglobulin A
(IgA)
• Angiotensin I • Immunoglobulin G
(IgG)
• Fructosamine • Immunoglobulin M
(IgM)
• Glucagon • Somatomedin-C
• Iron • TBG
• TIBC • Thyroglobulin
Does not Contains the following analytes:
• Homocysteine

--- Page 5 ---
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Not Applicable
b. Linearity/assay reportable range:
Not Applicable
c. Traceability, Stability, Expected values (controls, calibrators, or
methods):
Stability studies have been performed to determine the open vial stability and shelf
life for the Quest Diagnostics Immunoassay/TDM Control. Product claims and a
summary of the protocols used to establish claims are as follows:
• Open vial Stability: 7days when stored tightly capped at 2 to 8°C with the
following exceptions: C-Peptide, Folate and PSA are stable for 3 days and
Gastrin, Free PSA and Intact PTH should be assayed immediately after
reconstitution.
• Shelf Life: 36 months when stored at 2 to 8 °C
All supporting data is retained on file at Bio-Rad Laboratories.
The mean value presented in the Quest Diagnostics Immunoassay/TDM Control
product insert is generated by four Quest Diagnostics Laboratories. Mean values
were derived from replicate measurements from various Quest Laboratories and are
specific for each lot of product.
Quest Diagnostics Immunoassay/TDM Control Value assignment protocol
requires running all three levels of control lot five times for five testing days
resulting in 25 results per analyte. Proficiency testing performance should be
such that average SDI<1.0 and no SDI>3.0
d. Detection limit:
Not Applicable
e. Analytical specificity:
Not Applicable
f. Assay cut-off:
Not Applicable

--- Page 6 ---
2. Comparison studies:
a. Method comparison with predicate device:
Not Applicable
b. Matrix comparison:
Not Applicable
3. Clinical studies:
a. Clinical Sensitivity:
Not Applicable
b. Clinical specificity:
Not Applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not Applicable
4. Clinical cut-off:
Not Applicable
5. Expected values/Reference range:
Not Applicable
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part
809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and
supports a substantial equivalence decision.